View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 17, 2018

Novartis closes $8.7bn acquisition of AveXis

Novartis has completed the acquisition of clinical-stage gene therapy company AveXis for a total consideration of $8.7bn.

Novartis has completed the acquisition of clinical-stage gene therapy company AveXis for a total consideration of $8.7bn.

AveXis is now an indirect, wholly owned subsidiary of Novartis following the merger with its newly founded acquisition unit, Novartis AM Merger.

The complementary capabilities of the companies are expected to help transform the care of patients with life-threatening neurological genetic diseases.

AveXis’s experience, gene delivery platform, expertise, manufacturing and research and development (R&D) operations are set to support Novartis’ existing global footprint in neuroscience.

Novartis CEO Vas Narasimhan said: “Together, we now have the potential to bring to children the first one-time gene-based treatment for the devastating disease, spinal muscular atrophy.

“Together, we now have the potential to bring to children the first one-time gene-based treatment for the devastating disease, spinal muscular atrophy.”

“The deal also supports our strategy to deliver transformative innovation in areas of high unmet medical need, and advances our growing pipeline of gene therapies with the potential to transform the care of diseases, from [spinal muscular atrophy] (SMA) and cancer to blindness.”

SMA is a neurodegenerative disease caused by a defect in the survival motor neuron (SMN1) gene. AveXis is conducting various clinical studies for the treatment of this inherited condition.

The lead AveXis gene therapy candidate, AVXS-101, has ‘highly compelling’ clinical data in treating SMA Type 1.

This SMA type is the primary genetic cause of death in infants, with nine out of ten babies failing to survive until two years or being permanently dependent on a ventilator.

Narasimhan hopes that AVXS-101 will generate a ‘lifetime of possibilities’ for the children and families affected by the disease.

Related Companies

Free Report
img

Understand M&A activity across regions & sectors

Irrespective of market conditions, Mergers and Acquisitions continue to be on the table for global corporations. This was strongly evident when M&A volumes were relatively resilient to the disruption brought on by COVID-19, with only a slight decline in 2020 followed by a strong rebound in 2021. GlobalData's review provides you with insights on M&A trends, highlighting how deal activity shifts across key regions and industries. The deal types covered in our report include:
  • Mergers
  • Acquisitions
  • Asset transactions
  • Private equity buyouts
  • Mergers
  • Acquisitions
  • Asset transactions
  • Private equity buyouts
  • Mergers
  • Acquisitions
  • Asset transactions
  • Private equity buyouts
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU